Abstract |
Forty five patients with complicated urinary tract infections were treated with tosufloxacin (TFLX) in the initial antibacterial treatment. Excellent and moderate responses were obtained in 39 patients (86.7%). No side effects were seen. Clinical efficacy and safety of long-term preventive administration of TFLX (150mg, a day) were also examined in 39 patients who showed an excellent or a moderate response in the initial treatment. The period of the administration ranged from 28 to 112 days (average; 55 days). The rate of preventing recurrence of urinary tract infection was 92.3% on the last day of treatment. These findings suggested that TFLX was useful not only in treating the patients with complicated urinary tract infections but also in preventing recurrence of urinary tract infection.
|
Authors | M Sakurai, Y Sugimura, K Arima, J Kawamura, K Saitou, K Tajima, S Nakano, H Satani, M Nagano, A Hoshina |
Journal | Hinyokika kiyo. Acta urologica Japonica
(Hinyokika Kiyo)
Vol. 40
Issue 3
Pg. 279-84
(Mar 1994)
ISSN: 0018-1994 [Print] Japan |
PMID | 8178752
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Naphthyridines
- tosufloxacin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anti-Infective Agents
(administration & dosage, therapeutic use)
- Female
- Fluoroquinolones
- Humans
- Male
- Middle Aged
- Naphthyridines
(administration & dosage, therapeutic use)
- Recurrence
- Urinary Tract Infections
(drug therapy, prevention & control)
|